# Human Glycome Changes and Aging Pathology

Glycosylation is one of the most complex, highly regulated, and epigenetically directed post-translational modifications in human biology, involving the specific enzymatic attachment of complex carbohydrates—known as glycans—to proteins, lipids, and cellular membranes [cite: 1, 2]. While an organism's genomic sequence provides the static blueprint for cellular function, the glycome represents the dynamic realization of this blueprint. It functions as an integrator that maps genetic predisposition, epigenetic alterations, and environmental exposures into highly sensitive functional effectors [cite: 3, 4, 5]. In the context of gerontology and pathology, systemic alterations in glycosylation patterns—particularly those observed on the immunoglobulin G (IgG) molecule—serve simultaneously as predictive biomarkers of biological age and active drivers of age-related disease [cite: 5, 6, 7]. 

The progressive, age-associated shift toward a pro-inflammatory glycan profile contributes substantially to "inflammaging," a state of chronic, low-grade systemic inflammation recognized as a central transducer of organismal aging and tissue degradation [cite: 1, 3, 8]. This systemic inflammation integrates and amplifies upstream cellular damage, translating it into whole-organism dysfunction [cite: 3]. This report details the biochemical mechanisms governing age-related glycan changes, contrasts the utility of functional glycomic clocks with informational epigenetic aging clocks, evaluates the impact of geroprotective pharmacological interventions on glycan preservation, and maps the environmental plasticity of the human glycome across diverse global populations.

## Biochemical Architecture of Immunoglobulin G Glycosylation

Immunoglobulin G is an essential serum glycoprotein and a primary effector molecule of the humoral immune response. Its structural integrity, half-life, and effector functions are heavily modulated by glycans attached to a highly conserved N-glycosylation site located at asparagine 297 (Asn-297) within the second heavy chain (CH2) domain of the fragment crystallizable (Fc) region [cite: 9, 10, 11]. 

The N-glycans at the Asn-297 site exhibit substantial microheterogeneity. The foundational structure always consists of a biantennary complex-type heptaglycan core, which includes four N-acetylglucosamine (GlcNAc) and three mannose residues [cite: 10]. During biosynthesis in the endoplasmic reticulum and Golgi apparatus, this core structure is sequentially modified by approximately 200 glycosyltransferases and glycosylhydrolases [cite: 5, 12]. Four key enzymes—FUT8, B4GalT1, MGAT3, and ST6Gal1—are responsible for the production of the most common circulating glycoforms by appending specific monosaccharides [cite: 13]. This enzymatic processing yields over 30 distinct glycovariants that circulate in human serum [cite: 10]. 

In addition to the highly conserved Fc glycosylation, approximately 15% to 30% of human IgGs undergo somatic hypermutation events during affinity maturation that introduce novel N-glycosylation sites within the variable domain of the antigen-binding fragment (Fab) [cite: 10, 14]. While Fab glycosylation can affect antigen affinity and antibody stability, it is the Fc glycome that primarily dictates systemic inflammatory balance [cite: 10]. 

### Galactosylation and Sialylation Dynamics

The most prominent and consistently replicated biochemical alteration in the human glycome during aging is the progressive reduction of terminal galactose residues on the IgG Fc domain [cite: 6, 7, 15]. IgG glycoforms are generally categorized by the presence of these residues: agalactosylated (G0, lacking galactose), monogalactosylated (G1, containing one galactose), and digalactosylated (G2, containing two galactoses) [cite: 5, 10, 16]. In a healthy young adult, approximately 35% of IgGs possess G1 glycans, and 15% possess G2 glycans [cite: 10]. 

During normal human aging, the abundance of G0 glycans significantly increases, while G2 and terminally sialylated (S) glycans decrease [cite: 5, 14, 16]. The immunological consequences of this shift are profound. High galactosylation (G2) is fundamentally associated with anti-inflammatory activity; terminal galactoses enhance the binding of complement C1q, thereby promoting complement-dependent cytotoxicity (CDC) under regulated conditions and maintaining immune homeostasis [cite: 5, 14]. 

Furthermore, the addition of a terminal N-acetylneuraminic acid (sialic acid) to the galactose residues—present on approximately 10% to 15% of healthy IgGs—acts as an explicitly anti-inflammatory biological switch [cite: 5, 10]. Terminal α2,6-sialylation decreases the affinity of the Fc domain for activating Type I FcγRs while enabling engagement with Type II FcγRs and specific lectin receptors, such as DC-SIGN. This engagement increases the expression of the inhibitory receptor FcγRIIB and triggers widespread anti-inflammatory signaling cascades [cite: 5, 15]. The age-related loss of these sialylated and galactosylated structures deprives the immune system of a critical homeostatic brake, actively fostering the chronic immune activation characteristic of inflammaging [cite: 5, 6].

### Fucosylation and Bisecting N-Acetylglucosamine

Core fucosylation represents another defining feature of the human IgG glycome, with approximately 90% to 95% of circulating IgGs containing an α-1,6 fucose residue attached to the protein-adjacent GlcNAc [cite: 3, 10]. The presence of this core fucose sterically hinders the interaction between the IgG Fc domain and the activating receptor FcγRIIIA on effector leukocytes, such as natural killer (NK) cells and macrophages [cite: 5, 10]. Consequently, afucosylated IgG demonstrates an affinity for FcγRIIIA that is up to 100 times higher than that of its fucosylated counterpart, resulting in highly potent antibody-dependent cellular cytotoxicity (ADCC) [cite: 5, 11, 15]. While core fucosylation remains relatively stable during physiological aging, specific severe inflammatory states, viral infections, and distinct cardiometabolic diseases can rapidly alter fucose expression, deploying afucosylated antibodies as potent, tissue-destructive effectors [cite: 3, 10].

Conversely, the addition of a bisecting GlcNAc residue, which occurs in roughly 10% of IgGs, steadily increases with chronological age [cite: 5, 6, 10]. Bisecting GlcNAc functionally mimics some of the pro-inflammatory properties of afucosylation by enhancing ADCC and promoting binding to activating FcγRs, albeit with weaker potency [cite: 5]. A critical regulatory node in antibody biosynthesis is that the presence of a bisecting GlcNAc sterically inhibits the subsequent addition of core fucose [cite: 10]. Thus, the age-related increase in bisecting GlcNAc forces the production of antibodies that are inherently more cytotoxic, contributing to the age-related degradation of host tissues [cite: 5, 10].

## Structural Biology of the Fc Region

The specific monosaccharide composition of the Asn-297 glycan physically dictates the quaternary architecture of the IgG Fc region, illustrating how glycomic changes drive physical protein states. The structural biology of IgG Fc glycosylation can be conceptualized as a three-dimensional protein architecture interfacing with a highly specific carbohydrate network. When visualized as a ribbon model, the Asn-297 glycan protrudes into the interstitial space between the CH2 and CH3 domains. Applying the Symbol Nomenclature for Glycans (SNFG) conventions to the biantennary heptaglycan core, the structure consists of N-acetylglucosamine (blue squares) and mannose (green circles), which can be sequentially modified by the addition of galactose (yellow circles), core fucose (red triangles), and terminal sialic acid (purple diamonds).

Crystallographic analyses and small-angle X-ray scattering (SAXS) studies demonstrate that the CH2 domains pivot around a highly conserved "ball-and-socket" joint at the CH2-CH3 interface, formed by the CH2 L251 side chain interacting with a pocket comprising CH3 M428, H429, E430, and H435 [cite: 17]. Fully glycosylated Fc regions maintain an "open" conformation stabilized by carbohydrate-protein interactions, which is optimal for leukocyte FcγR docking [cite: 18, 19]. 

The progressive age-related loss of terminal yellow (galactose) and purple (sialic acid) residues physically collapses this interstitial space, establishing a closed structural dynamic. Early crystallographic data suggested that aglycosylated Fc molecules collapse into a rigid, "super-closed" state that completely abrogates receptor binding due to steric incompatibility [cite: 19]. However, recent evaluations utilizing SAXS in physiological solutions reveal that the aglycosylated Fc displays a larger radius of gyration (Rg of 28.3 ± 0.1 Å) compared to the fully glycosylated Fc (Rg of 27.4 ± 0.1 Å) [cite: 18]. This indicates that both glycosylated and aglycosylated Fc domains adopt a highly dynamic "semi-closed" orientation in solution [cite: 9, 18]. The age-related loss of glycans, therefore, abrogates immune function not merely by collapsing the global Fc structure, but by directly eliminating the carbohydrate-carbohydrate and carbohydrate-receptor interactions required to initiate the ADCC and CDC signaling cascades [cite: 18]. 

## Glycomic Biological Aging Clocks

The highly predictable trajectory of IgG glycan deterioration has facilitated the development of molecular aging clocks. The ability to quantify the physiological wear-and-tear on an organism enables the differentiation of health status among individuals sharing the same chronological age [cite: 20]. Multivariate regression models combining multiple glycan traits—such as the ratio of agalactosylated (G0) to digalactosylated (G2) structures alongside bisecting GlcNAc incidence—can explain up to 58% of the variance in human chronological age [cite: 21, 22, 23]. The remaining variance strongly correlates with physiological parameters associated with biological aging, cardiometabolic risk, and immune senescence [cite: 21, 22].

### Glycomic Versus Epigenetic Aging Clocks

While both epigenetic (DNA methylation) and glycomic clocks are highly robust predictors of biological age, they capture fundamentally different, non-overlapping dimensions of aging biology [cite: 1, 24].

Epigenetic clocks—including first-generation models like the Horvath pan-tissue clock (based on 353 CpG sites) and the blood-specific Hannum clock, as well as second-generation outcome-trained models like DNAm PhenoAge, DNAm GrimAge, and the DunedinPACE pace-of-aging metric—evaluate the methylation status of cytosine residues across the genome [cite: 2, 24, 25]. These models capture the informational deterioration of genomic regulation and cellular differentiation [cite: 1, 26]. Epigenetic clocks are exceptionally accurate at predicting chronological age, mortality risk, and cross-tissue vulnerability [cite: 25, 27, 28]. However, the exact functional pathways governed by many targeted CpG sites remain partially obscure, rendering methylation changes highly correlative [cite: 1, 29].

In contrast, glycan clocks (such as the GlycanAge index) measure changes at the level of functional systemic effectors [cite: 1]. Because IgG glycans directly modulate immune cell activation, they are not merely passive witnesses to the aging process; they are active mediators of systemic pathology [cite: 2, 3, 24]. This distinction defines their differing clinical utility: epigenetic models excel at forecasting long-term morbidity and assessing fixed genetic risks, whereas glycomic models provide a real-time, highly plastic snapshot of current inflammatory burden and cardiometabolic vulnerability [cite: 1, 24, 30]. 

| Biological Aging Metric | Target Substrate and Biomarker | Primary Mechanistic Role in Aging | Actionability and Plasticity | Clinical Application |
| :--- | :--- | :--- | :--- | :--- |
| **Epigenetic Clocks** (e.g., GrimAge, PhenoAge) | DNA methylation patterns at specific CpG dinucleotide sites [cite: 24, 25] | Genomic regulation, epigenetic drift, and cellular differentiation deterioration [cite: 1, 26] | Moderate. Metrics like DunedinPACE track intervention pace, but general clocks reflect highly stable systemic decline [cite: 24, 25, 29]. | Excellent for long-term all-cause mortality risk stratification and evaluating tissue-specific pace of aging [cite: 24, 25, 29]. |
| **Glycomic Clocks** (e.g., GlycanAge) | N-glycan structures attached to the IgG Fc region (Asn-297) [cite: 1, 30] | Immune system modulation, driving chronic low-grade systemic inflammation ("inflammaging") [cite: 3, 24, 30] | High. Highly responsive to near-term lifestyle changes, dietary interventions, exercise, and pharmacology [cite: 24, 30, 31, 32]. | Excellent for assessing current inflammatory status, tracking lifestyle intervention efficacy, and predicting cardiometabolic risk [cite: 3, 24, 30]. |
| **Telomere Length Analysis** | Terminal DNA sequence repeats (TTAGGG) via TRF or PCR assays [cite: 24, 28] | Cellular replicative history, telomere attrition, and replicative senescence [cite: 21, 24, 28] | Low to Moderate. Highly variable depending on assay noise and genetic baseline; slow to reflect lifestyle changes [cite: 24, 28]. | Niche utility. Useful for diagnosing specific telomere biology disorders, but often less reliable as a general health span tracker [cite: 24]. |

In comparative validation studies assessing molecular aging clocks against health outcomes, IgG glycomics frequently outperforms other indices (including telomere length and composite clinical clinical clocks) at predicting future hospitalization events due to broad systemic issues, including severe viral infections, circulatory diseases, and metabolic dysfunction [cite: 4, 21, 22]. Furthermore, accelerated glycan aging exhibits a strong correlation with increased all-cause mortality, functioning independently of traditional clinical risk factors [cite: 3, 33].

### Integration With High-Throughput Multi-Omics

Historically, the structural analysis of glycans was an arduous process, limited by the need for extensive sample preparation and the specialized use of high-performance liquid chromatography (HPLC) coupled with fluorescence detection. While HPLC successfully identifies relative proportions of glycan pools, it obscures absolute concentrations and introduces significant interpretative variability [cite: 34, 35]. 

The field is currently undergoing a renaissance driven by high-throughput platforms. Innovations such as the cotton-based GlycoPro 96-well plate platform and MALDI-TOF mass spectrometry allow for the rapid enrichment, desalting, and absolute quantification of glycopeptides across massive clinical cohorts [cite: 34, 35, 36]. By shifting from relative ratios to absolute concentration models, researchers have identified critical early-stage aging signatures, such as the profound absolute downregulation of the bisected glycan GP3 (F(6)A2B) and upregulation of the digalactosylated glycan GP8 (F(6)A2G2) [cite: 34, 35]. 

These high-throughput capabilities have enabled the seamless integration of glycomics into the broader multi-omics framework, combining data from genomics, transcriptomics, epigenomics, and metabolomics [cite: 8, 20, 26]. A unified multi-omics approach corrects the blind spots of reductionist biology [cite: 26, 37]. For example, the integration of single-cell RNA sequencing (scRNA-seq) with spatial omics and glycomics reveals that specific B-cell subpopulations suffer transcriptomic dysregulation of glycosyltransferases long before macroscopic aging phenotypes appear [cite: 13, 38]. Furthermore, epigenomic research into Pathological Epigenetic Events that are Reversible (PEERs)—epigenetic marks linked to early-life environmental exposures—demonstrates how early developmental stress permanently alters the regulatory networks governing the immune glycome in adulthood [cite: 26, 37, 39]. Advanced machine learning algorithms applied to these integrated datasets can now classify heterogeneous aging trajectories, mapping exactly where upstream transcriptomic noise translates into the downstream loss of protective IgG galactosylation [cite: 20, 38].

## Glycan Dysregulation in Age-Related Pathologies

The age-driven drift toward an agalactosylated, pro-inflammatory IgG glycome is heavily implicated in the pathogenesis of specific chronic diseases. The analysis of over 20,000 individuals across 42 different studies confirms that specific pathological IgG glycome profiles often emerge years prior to clinical disease manifestation, positioning glycans as both causal drivers and early warning indicators [cite: 3, 33].

### Cardiometabolic and Renal Disease

Cardiovascular disease (CVD) and type 2 diabetes (T2D) are the primary drivers of mortality in aging populations, and both are deeply intertwined with glycomic alterations. Comprehensive cohort studies, including the EPIC-Potsdam cohort, demonstrate that specific IgG N-glycan peaks independently predict incident T2D and CVD events beyond classic clinical risk factors [cite: 40]. After extensive confounder adjustment, elevated levels of specific agalactosylated and bisected glycans (notably GP7, GP8, GP9, GP11, and GP19) strongly correlate with future T2D incidence. In meta-analyses, a composite score of these pro-inflammatory glycans carried a pooled hazard ratio of 1.50 per standard deviation increase in risk for developing T2D [cite: 40].

Glycomic profiles predicting incident CVD exhibit notable sexual dimorphism. In men, a weighted score based on GP19 and GP23 is associated with significantly higher CVD risk (hazard ratio 1.47), whereas in women, the presence of specific sialylated glycans (such as GP9) demonstrates an inverse, protective association against vascular events [cite: 40]. In the context of renal function, the loss of digalactosylated and sialylated glycans (specifically peaks GP14 and GP18) is heavily associated with an accelerated decline in the estimated glomerular filtration rate (eGFR) and the rapid onset of diabetic nephropathy [cite: 41]. 

### Autoimmunity and Variable Domain Glycosylation

The collapse of glycomic immune regulation precipitates autoimmune pathology. Conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are characterized by severe, premature deficits in IgG galactosylation and sialylation [cite: 5, 14]. In RA patients, the profound lack of galactosylation eliminates the anti-inflammatory function of IgG, allowing autoantibodies to relentlessly attack synovial tissues [cite: 5].

Emerging research highlights the critical role of Variable Domain Glycosylation (VDG) in autoimmune dynamics. While normal Fc glycans dictate effector binding, VDGs directly modulate antibody oligomerization. In RA and certain B-cell malignancies, an overabundance of VDGs on IgG antibodies structurally inhibits the classical complement pathway by disrupting the antibody's ability to oligomerize and bind C1q [cite: 42]. This rogue structural modification allows pathological B-cells and autoantibodies to evade immune clearance, sustaining chronic autoimmune inflammation [cite: 42].

### The Glycocalyx and Blood-Brain Barrier Integrity

Beyond circulating immunoglobulins, the dysregulation of glycans attached to cell surface proteins severely degrades localized tissue architecture, particularly at the blood-brain barrier (BBB). Endothelial cells comprising the BBB are coated in a dense, heavily glycosylated layer known as the glycocalyx [cite: 43]. 

In a young, healthy central nervous system, this lush glycocalyx acts as a highly selective structural filter, preventing neurotoxic molecules from penetrating brain tissue. However, aging induces the degradation of this barrier; the glycocalyx becomes sparse and patchy due to a stark reduction in heavily glycosylated, bottlebrush-shaped proteins called mucins [cite: 43]. This age-related loss of the carbohydrate shield compromises BBB integrity, increasing vascular permeability. The subsequent infiltration of peripheral inflammatory mediators fuels neuroinflammation, directly accelerating cognitive decline and establishing the microenvironment necessary for neurodegenerative pathologies such as Alzheimer's disease [cite: 43]. Experimental models demonstrate that targeted interventions restoring critical mucins in aged subjects successfully rebuild the glycocalyx architecture, reduce neuroinflammation, and measurably improve cognitive function, confirming that glycan preservation is a vital component of neuroprotection [cite: 43].

### Lectin and Galectin Immune Evasion

The biological information encoded within complex cell-surface glycans is deciphered by highly conserved carbohydrate-binding proteins known as lectins, which include Galectins and Siglecs (sialic acid-binding immunoglobulin-like lectins) [cite: 12]. 

Galectins, a family of soluble proteins that specifically bind β-galactoside-containing glycans, form multivalent, two- and three-dimensional supramolecular lattice structures on the cell surface. These galectin-glycan lattices regulate vital cellular events, including receptor turnover, signal transduction, homotypic cell aggregation, and apoptosis [cite: 12, 44]. For example, the dimerization of galectin-8 is essential for signaling phosphatidylserine (PS) exposure in leukocytes [cite: 44]. 

During aging and oncogenesis, aberrant glycosylation patterns disrupt these homeostatic lattices [cite: 12]. Tumor cells exploit this vulnerability to evade immune detection. By artificially upregulating surface sialylation, malignant cells engage inhibitory Siglec receptors located on the surface of hematopoietic and immune cells. This rogue interaction effectively dampens both innate and adaptive immune responses, facilitating uninhibited tumor growth and metastasis [cite: 12, 45]. 

## Pharmacological Modulation of the Glycome

Because the human glycome functions as a dynamic, environmentally responsive matrix, it is highly sensitive to geroprotective pharmacological interventions. A summary of how primary metabolic and immunosuppressive therapies intersect with aging pathways and modify the inflammatory state of the human IgG glycome highlights the pleiotropic effects of these distinct drug classes.

Statins, primarily indicated for hypercholesterolemia and cardiovascular disease prevention, operate primarily by reducing systemic inflammation and vascular vulnerability. In the context of the glycome, statins decrease specific monosialylated and core fucosylated IgG N-glycans (GP16, GP18, GP21). The clinical evidence for this effect is moderate, though the interaction exhibits significant complexity across different patient cohorts. 

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), utilized for Type 2 diabetes and obesity, induce systemic molecular age reversal and enhance mitochondrial function. Crucially, they dampen systemic oxidative stress and "inflammaging," thereby supporting the maintenance of a more youthful, galactosylated glycan profile. The evidence supporting their broad systemic anti-aging utility is currently categorized as strong.

Sodium-glucose cotransporter-2 inhibitors (SGLT2is), prescribed for Type 2 diabetes, heart failure, and chronic kidney disease, yield profound cardioprotective and renoprotective benefits by reducing cellular senescence and suppressing interleukins like IL-6. Glycomically, the slower decline in beneficial digalactosylated and sialylated peaks (GP14, GP18) is strongly correlated with reduced incidence of nephropathy in patients using SGLT2is. 

Finally, mTOR inhibitors, such as rapamycin, extend lifespan via senomorphic action and direct DNA damage reduction. By suppressing the Senescence-Associated Secretory Phenotype (SASP), rapamycin indirectly halts the pro-inflammatory deterioration of the glycome. The evidence for its systemic lifespan extension in clinical models is strong, though its specific interaction with IgG glycosylation relies on emerging, indirect evidence pathways.

### Statins and Cardiovascular Glycomic Markers

Statins, widely prescribed HMG-CoA reductase inhibitors utilized for cardiovascular prevention, exhibit pleiotropic immunomodulatory effects that reflect dynamically in the IgG glycome [cite: 46]. In randomized, double-blind trials—including specific sub-studies of the JUPITER (rosuvastatin) and TNT (atorvastatin) cohorts—high-intensity statin therapy induced reproducible alterations in specific IgG N-glycan levels [cite: 47, 48]. 

Statins significantly decreased the levels of monosialylated, disialylated, and core fucosylated glycans (specifically identified as glycan peaks GP16, GP17, GP18, GP21, and GP23) by approximately 11.3% to 25.9% over a one-year intervention [cite: 47, 48]. In the JUPITER trial, lower baseline levels of monosialylated and core fucosylated glycans (GP16 and GP18) were inversely associated with incident CVD events (Odds Ratio = 0.87 and 0.73 per standard deviation increase, respectively) [cite: 48]. This indicates that the statin-induced reduction of these specific glycans may enhance the cardioprotective properties of circulating immunoglobulins [cite: 47, 48]. 

However, these findings require careful calibration. The overall architecture of the IgG N-glycan connectivity network remained largely unchanged post-intervention [cite: 47, 48]. Furthermore, observational population cohorts, such as TwinsUK and KORA, have reported that statin use was occasionally associated with a slight increase in pro-inflammatory glycan structures containing bisecting GlcNAc (FA2B), indicating that the interaction between statins and the glycome is complex, dose-dependent, and heavily influenced by underlying metabolic health [cite: 46, 49].

### GLP-1 Receptor Agonists

Originally developed for glycemic control in T2D, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and exenatide have emerged as transformative metabolic modulators with profound anti-aging properties [cite: 50, 51]. 

GLP-1RAs exhibit pleiotropic effects that counter aging across multiple organ systems by enhancing mitochondrial function, improving cellular quality control, and reducing oxidative stress and chronic inflammation [cite: 50, 51, 52]. These systemic improvements occur independently of the drugs' well-documented effects on weight loss and appetite suppression [cite: 51, 53]. Multi-omics evaluations in aging murine models demonstrate that systemic administration of GLP-1RAs alters transcriptomic, epigenomic, and metabolomic signatures in a manner comparable to the gold-standard longevity drug rapamycin [cite: 53, 54]. Notably, while rapamycin exerts stronger transcriptional corrections in the brain, GLP-1RAs (exenatide) induce superior transcriptomic rejuvenation in skeletal muscle, reversing physical decline and increasing genes involved in mitochondrial health [cite: 53]. 

By systemically lowering oxidative stress and neutralizing the cellular drivers of inflammation, GLP-1RAs theoretically protect the B-cell biosynthetic machinery, preserving the cellular environment necessary for robust IgG galactosylation and shielding the organism from glycome collapse [cite: 51, 52]. Clinical outcomes reflect this preservation; pooled analyses demonstrate that GLP-1RAs reduce Major Adverse Cardiovascular Events (MACE) by 14% to 20% and lower the risk of severe infections like pneumonia by 28% [cite: 50, 53]. 

### SGLT2 Inhibitors and Renal Protection

Sodium-Glucose Cotransporter-2 inhibitors (SGLT2is), including dapagliflozin, empagliflozin, and canagliflozin, lower blood glucose by promoting glycosuria, but their secondary cardioprotective and renoprotective effects mark them as vital gerotherapeutics [cite: 51, 55, 56]. 

SGLT2is effectively mitigate the progression of diabetic kidney disease, IgA nephropathy, and heart failure by reducing intraglomerular pressure, alleviating tubular cell injury, and suppressing renal inflammation [cite: 55, 56, 57]. Clinical trial data demonstrate that 6 weeks of dapagliflozin therapy dramatically decreased albuminuria by 43.9%, urinary Kidney Injury Molecule-1 (KIM-1) excretion by 22.6%, and the pro-inflammatory cytokine Interleukin-6 (IL-6) by 23.5% [cite: 57, 58]. Furthermore, empagliflozin administration actively prevents diabetes-induced mitochondrial fission by activating the AMPK pathway, thereby restoring mitochondrial morphology and function [cite: 59].

From a glycomic perspective, the preservation of specific IgG glycans is heavily intertwined with renal outcomes. Large cohort analyses reveal that higher baseline levels of digalactosylated (GP14) and monosialylated/digalactosylated (GP18) IgG glycans are significantly associated with a lower risk of developing chronic kidney disease, diabetic nephropathy, and peripheral artery disease [cite: 41]. By neutralizing systemic IL-6 levels and resolving localized tubuloglomerular inflammation, SGLT2 inhibitors counteract the physiological environments that typically drive the rapid, age-related agalactosylation of the IgG pool [cite: 41, 57, 59].

### mTOR Inhibition and Metformin

Rapamycin, a macrolide initially recognized as an antifungal and immunosuppressant, operates by inhibiting the mechanistic target of rapamycin (mTOR) pathway. Specifically, it blocks mTOR complex 1 (mTORC1), a master kinase that regulates cell growth, protein synthesis, and metabolism [cite: 53, 60, 61]. Because mTORC1 activity inappropriately increases with age—contributing to a loss of proteostasis and mitochondrial dysfunction—its inhibition represents one of the most robust life-extending pharmacological interventions documented across species [cite: 60, 62, 63].

Recent in vivo human studies, such as the placebo-controlled PEARL trial in older adults, demonstrate that low-dose, intermittent rapamycin is well-tolerated and yields tangible improvements in biomarkers of biological aging [cite: 60, 62]. Crucially, rapamycin functions as a direct genoprotectant. In human T-cells exposed to genotoxic stress, mTOR inhibition suppresses senescence not by merely halting cell division or artificially stimulating autophagy, but by directly reducing the cellular DNA lesional burden [cite: 62]. This results in significantly lower levels of p21, a primary marker of DNA damage-induced senescence [cite: 62]. By attenuating the Senescence-Associated Secretory Phenotype (SASP) and minimizing the systemic release of inflammatory cytokines, rapamycin limits the environmental cues that trigger pro-inflammatory glycan shifting [cite: 14, 59, 62].

Rapamycin's efficacy is often evaluated alongside Metformin and Acarbose, two established antidiabetic agents that share overlapping anti-aging mechanisms [cite: 61, 63]. Metformin operates as a mild mTOR inhibitor and AMPK activator, lowering hepatic gluconeogenesis while yielding pleiotropic cardiovascular and anti-cancer benefits [cite: 54, 61, 63]. Acarbose, an alpha-glucosidase inhibitor, modulates nutrient-sensing pathways by blunting postprandial glucose spikes [cite: 63]. The strategic combination of these compounds—leveraging rapamycin's direct genoprotection alongside metformin and acarbose's mimicry of caloric restriction—is theorized to generate synergistic geroprotective effects, comprehensively shielding the organism's metabolic and glycomic infrastructure from age-related degradation [cite: 61, 63]. 

## Environmental Plasticity and Population Diversity

The human glycome is not a rigid, deterministic phenotype. While average IgG glycome heritability is estimated at approximately 50%, the remaining 50% of phenotypic variance is entirely dictated by environmental exposures, dietary habits, and unique lifestyle choices [cite: 14, 32]. This high environmental plasticity establishes the glycome as an exquisite biological ledger, recording an individual's accumulated lifetime exposures and rendering the glycan aging clock uniquely reversible [cite: 32, 64]. 

### Demographic and Geographic Variability

Extensive global analyses—encompassing over 10,000 completely mapped IgG N-glycomes from more than 27 culturally and geographically distinct populations across 14 countries—reveal extraordinary baseline diversity in human glycosylation patterns [cite: 14, 65, 66].

A critical finding from these population-scale studies is that the degree of IgG monogalactosylation within a cohort correlates strongly with the socioeconomic development level of their country of residence, as defined by United Nations health indicators [cite: 14, 65, 67]. Subjects residing in developing nations, or regions burdened by high infectious disease prevalence and chronic environmental stressors, exhibit severely suppressed baseline levels of IgG galactosylation [cite: 65, 66, 67]. 

For example, populations sampled from Papua New Guinea, despite being chronologically younger on average, demonstrated surprisingly high median levels of agalactosylation (45%) on the IgG1 subclass. In stark contrast, highly developed cohorts from England exhibited significantly lower levels of agalactosylation (28%) [cite: 14, 66]. This geographic disparity indicates that endemic pathogens, nutritional deficits, and socioeconomic hardship induce a state of chronic, low-grade systemic inflammation, causing individuals in under-resourced regions to present with an accelerated biological "glycan age" that far exceeds their chronological age [cite: 65, 66, 67]. 

Demographic factors such as biological sex further differentiate glycomic trajectories. Women exhibit a distinct, sharp decline in IgG galactosylation and sialylation, alongside an abrupt increase in bisecting GlcNAc, occurring specifically between the ages of 45 and 55 [cite: 14, 68]. This dramatic pro-inflammatory shift coincides with the onset of menopause and the decline of estrogen, a hormone biologically proven to promote galactosylation and suppress systemic inflammation [cite: 14]. 

### The Role of the Gut Microbiome

The diversity of the human glycome is intricately linked to the composition of the gut microbiome, which exhibits its own extreme geographic and dietary variation. Analyses of fecal microbiomes from isolated Amerindian communities in the Venezuelan Amazonas, rural Malawian agriculturalists, and inhabitants of US metropolitan areas reveal pronounced disparities [cite: 69, 70]. Western populations, subsisting on high-protein, heavily processed diets, are heavily dominated by the *Bacteroides* genus. Conversely, non-Western, foraging, or agricultural populations relying on fiber-rich, plant-based diets (such as corn and cassava) exhibit a vast taxonomic richness dominated by the *Prevotella* genus [cite: 69, 71]. 

The microbiome directly modulates systemic inflammation and, consequently, the state of the glycome [cite: 72, 73]. High consumption of dietary Advanced Glycation Endproducts (AGEs)—compounds prevalent in highly processed, Western diets—accumulate rapidly in plasma, renal, and hepatic tissues. This dietary accumulation severely disrupts the gut microbiota (favoring species like *Dubosiella spp.*) and triggers widespread systemic inflammation [cite: 72]. Because the immune glycome is highly responsive to inflammatory cytokines originating from gut dysbiosis, the westernization of the microbiome directly accelerates the age-related agalactosylation of IgG [cite: 69, 72]. 

### Lifestyle Factors and Dietary Reversibility

The inherent plasticity of the glycome means that interventions targeting the concept of "ground-state prevention"—stalling the age-related accumulation of molecular damage to boost resilience—can successfully rewind the biological clock [cite: 64, 74]. 

Pathological IgG glycan profiles progressively worsen under the strain of modifiable lifestyle factors, including high Body Mass Index (BMI), chronic smoking, and heavy alcohol consumption [cite: 68]. Repeated longitudinal measurements confirm that these behaviors force the glycome into a premature pro-inflammatory phenotype [cite: 68]. 

However, longitudinal intervention studies demonstrate that correcting these behaviors actively rejuvenates the glycome. Significant weight loss, whether achieved through sustained caloric restriction, personalized AI-driven nutrigenetic dietary interventions, or bariatric surgery, rapidly reverses the pro-inflammatory agalactosylated signature [cite: 32, 34, 75]. In morbidly obese patients, adherence to a multi-omics tailored nutrition plan not only reduced BMI but significantly decreased the GlycanAge index by an average of 8 years over a six-month period [cite: 75]. Furthermore, medical interventions such as hormone replacement therapy (HRT) in menopausal women and therapeutic plasma exchange (TPE) effectively reverse accelerated glycan aging, confirming that the biological aging clock can be actively managed and dialed back through precise environmental and clinical inputs [cite: 32, 33].

## Conclusion

The human glycome represents a critical, highly sensitive nexus in the biology of aging, translating static genetic code, environmental stress, and systemic metabolic health into a functional inflammatory state. The age-related deterioration of the IgG N-glycome—specifically characterized by the catastrophic loss of terminal galactose and sialic acid residues, and the relative accumulation of bisecting GlcNAc—is not merely a passive symptom of chronological aging. It is an active, mechanistic driver of the "inflammaging" cascade that precipitates cardiometabolic failure, autoimmune disorders, and neurodegenerative decline. 

Unlike purely informational epigenetic clocks that record the trajectory of genomic regulation, the glycome operates as a functional effector matrix. Its high environmental plasticity renders it an exceptional, highly responsive biological target. Pharmacological interventions—ranging from the pleiotropic effects of GLP-1 receptor agonists and SGLT2 inhibitors to the direct genoprotection of mTOR inhibitors—alongside rigorous lifestyle and dietary modifications, possess the demonstrated capacity to stabilize and actively reverse pathological glycan drift. As high-throughput, single-cell multi-omics technologies continue to mature, the precise mapping of the glycome's temporal and spatial dynamics will remain an essential foundation for the deployment of personalized, geroprotective medicine aimed at preserving immune homeostasis and extending human healthspan.

## Sources

1. [Biological Age Tests Compared](https://glycanage.com/frequently-asked-questions/biological-age-tests-compared)
2. [PMC4049143](https://pmc.ncbi.nlm.nih.gov/articles/PMC4049143/)
3. [Fight Aging: Glycosylation Clocks](https://www.fightaging.org/archives/2024/08/a-look-at-the-basis-for-glycosylation-clocks-to-measure-biological-age/)
4. [TruDiagnostic vs GlycanAge](https://lolahealth.com/blogs/longevity/trudiagnostic-vs-glycanage-which-biological-age-test-should-you-choose)
5. [Glycans as Biomarkers of Age](https://kclpure.kcl.ac.uk/portal/en/publications/glycans-are-a-novel-biomarker-of-chronological-and-biological-age/)
6. [PMC11908345](https://pmc.ncbi.nlm.nih.gov/articles/PMC11908345/)
7. [Statin Effects on IgG Glycomic Architecture](https://research.bidmc.org/ncfg/publications/statin-effects-immunoglobulin-g-glycomic-architecture-and-link-cardiovascular-disease)
8. [PMC5441970](https://pmc.ncbi.nlm.nih.gov/articles/PMC5441970/)
9. [PubMed: 28263871](https://pubmed.ncbi.nlm.nih.gov/28263871/)
10. [MDPI: 2077-0383/15/8/3056](https://www.mdpi.com/2077-0383/15/8/3056)
11. [Epigenetic vs Glycan Ageing Clocks](https://glycanage.com/blog/health/epigenetic-vs-glycan-ageing-clocks-which-is-better-for-measuring-biological-age)
12. [PMC12905613](https://pmc.ncbi.nlm.nih.gov/articles/PMC12905613/)
13. [Aging-US: 206098](https://www.aging-us.com/article/206098/text)
14. [Epigenetic Clock Aging Biomarkers](https://www.patsnap.com/resources/blog/rd-blog/epigenetic-clock-aging-biomarkers-2026-patsnap-eureka/)
15. [Frontiers: Oncology 2016](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2016.00109/full)
16. [ResearchGate: IgG Glycan Structures](https://www.researchgate.net/figure/IgG-glycan-structures-and-the-known-glycosylation-pathway-IgG-glycans-are-biantennary_fig5_321059386)
17. [GlycanSwitch Publications](https://glycanswitch.com/publications)
18. [PMC3429939](https://pmc.ncbi.nlm.nih.gov/articles/PMC3429939/)
19. [NCBI Bookshelf: NBK579987](https://www.ncbi.nlm.nih.gov/books/NBK579987/)
20. [Rapamycin and Longevity Benefits](https://www.aging-us.com/news-room/rapamycin-shows-limited-evidence-for-longevity-benefits-in-healthy-adults)
21. [PMC12226543](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/)
22. [PMC8190242](https://pmc.ncbi.nlm.nih.gov/articles/PMC8190242/)
23. [bioRxiv: 670559v1](https://www.biorxiv.org/content/10.1101/2025.08.15.670559v1.full-text)
24. [Aging-US: 206300](https://www.aging-us.com/article/206300/text)
25. [ResearchGate: GlycAge vs Epigenetic Clocks](https://www.researchgate.net/figure/Relationship-between-GlycAge-and-other-biological-age-clocks-in-the-n-26-participants_fig5_394213363)
26. [Cambridge: Biomarkers to Assess Aging](https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/article/potential-noninvasive-biomarkers-to-assess-the-aging-process/319E222110EBD6F4BE7AE7A59F1D3EA3)
27. [Let's Prolong Life: Biological Age](https://letsprolonglife.com/biological-age/)
28. [Hillary Lin MD: Longevity Upgrade](https://hillarylinmd.com/article/your-2026-longevity-upgrade-brain-mitochondria-part-2)
29. [MDPI: 1422-0067/25/12/6793](https://www.mdpi.com/1422-0067/25/12/6793)
30. [PubMed: 39383621](https://pubmed.ncbi.nlm.nih.gov/39383621/)
31. [arXiv: 2510.12384v1](https://arxiv.org/html/2510.12384v1)
32. [PubMed: 40684321](https://pubmed.ncbi.nlm.nih.gov/40684321/)
33. [MDPI: 1422-0067/25/24/13671](https://www.mdpi.com/1422-0067/25/24/13671)
34. [Engineering.org.cn: 2025.01.011](https://www.engineering.org.cn/engi/EN/10.1016/j.eng.2025.01.011)
35. [Time in Newcastle upon Tyne](https://www.google.com/search?q=time+in+Newcastle+upon+Tyne,+GB)
36. [PMC3448853](https://pmc.ncbi.nlm.nih.gov/articles/PMC3448853/)
37. [PMC6512918](https://pmc.ncbi.nlm.nih.gov/articles/PMC6512918/)
38. [ACS Central Science: 4c01157](https://pubs.acs.org/doi/10.1021/acscentsci.4c01157)
39. [PubMed: 23628091](https://pubmed.ncbi.nlm.nih.gov/23628091/)
40. [ACS Chemical Biology: cb300130k](https://pubs.acs.org/doi/10.1021/cb300130k)
41. [PMC5972252](https://pmc.ncbi.nlm.nih.gov/articles/PMC5972252/)
42. [TMGHIG Research Topics](https://www.tmghig.jp/research/en/etopics/archives/015664/)
43. [Stanford APARC: Asia's Aging Populations](https://aparc.fsi.stanford.edu/news/asias-aging-populations-drive-surging-disease-burden-although-individual-health-improves)
44. [PMC6175034](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175034/)
45. [Duke Kunshan University: Aging Research Gaps](https://news.dukekunshan.edu.cn/research-news/study-maps-aging-and-health-research-gaps-across-east-and-southeast-asia/)
46. [PubMed: 41072556](https://pubmed.ncbi.nlm.nih.gov/41072556/)
47. [Frontiers: Clinical Diabetes and Healthcare](https://www.frontiersin.org/journals/clinical-diabetes-and-healthcare/articles/10.3389/fcdhc.2024.1530811/full)
48. [e-DMJ: 0242](https://e-dmj.org/journal/view.php?doi=10.4093/dmj.2025.0242)
49. [MDPI: 1999-4923/17/8/1036](https://www.mdpi.com/1999-4923/17/8/1036)
50. [Glaucoma Physician: GLP-1 RA Impact](https://www.glaucomaphysician.net/issues/2025/september/the-impact-of-glp1-receptor-agonists-on-ocular-disease/)
51. [BioWorld: Multiomic Study on GLP-1RAs](https://www.bioworld.com/articles/726345-multiomic-study-shows-antiaging-effects-of-glp-1ras)
52. [Aging with Strength: GLP-1 Primer](https://www.agingwithstrength.com/p/glp-1-metformin-and-rapamycin-a-primer)
53. [PMC11812426](https://pmc.ncbi.nlm.nih.gov/articles/PMC11812426/)
54. [PMC11354721](https://pmc.ncbi.nlm.nih.gov/articles/PMC11354721/)
55. [NMN.com: GLP-1 Drug Counteracts Aging](https://www.nmn.com/news/glp-1-drug-counteracts-aging-independent-of-weight-loss-in-new-study)
56. [PMC11399422](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399422/)
57. [Frontiers: Immunology 2022](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.929895/full)
58. [PubMed: 39126246](https://pubmed.ncbi.nlm.nih.gov/39126246/)
59. [PMC7109348](https://pmc.ncbi.nlm.nih.gov/articles/PMC7109348/)
60. [Aging-US: 103884 Text](https://www.aging-us.com/article/103884/text)
61. [Aging-US: 103884](https://www.aging-us.com/article/103884)
62. [bioRxiv: 535237v1](https://www.biorxiv.org/content/10.1101/535237v1.full-text)
63. [ResearchGate: Global Variability of Human IgG Glycome](https://www.researchgate.net/publication/343643067_Global_variability_of_the_human_IgG_glycome)
64. [PubMed: 42059102](https://pubmed.ncbi.nlm.nih.gov/42059102/)
65. [Engineering.org.cn: 2025.07.042](https://www.engineering.org.cn/engi/EN/10.1016/j.eng.2025.07.042)
66. [PubMed: 39383621](https://pubmed.ncbi.nlm.nih.gov/39383621/)
67. [bioRxiv: 631349v1](https://www.biorxiv.org/content/10.1101/2025.01.05.631349v1.full-text)
68. [Aging and Disease: 0218](https://www.aginganddisease.org/EN/10.14336/AD.2025.0218)
69. [ResearchGate: Multiomics in Aging Research](https://www.researchgate.net/publication/393846277_The_emerging_role_of_multiomics_in_aging_research)
70. [PMC9245174](https://pmc.ncbi.nlm.nih.gov/articles/PMC9245174/)
71. [Epigenetic vs Glycan Ageing Clocks](https://glycanage.com/blog/health/epigenetic-vs-glycan-ageing-clocks-which-is-better-for-measuring-biological-age)
72. [medRxiv: 22272417v1](https://www.medrxiv.org/content/10.1101/2022.03.15.22272417v1.full-text)
73. [PMC6055757](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055757/)
74. [PMC9679264](https://pmc.ncbi.nlm.nih.gov/articles/PMC9679264/)
75. [Journal of Endocrinology and Metabolism: 531](https://jofem.org/index.php/jofem/article/view/531/284284332)
76. [ResearchGate: Effects of Dapagliflozin](https://www.researchgate.net/publication/323997399_Effects_of_the_SGLT-2_inhibitor_dapagliflozin_on_glomerular_and_tubular_injury_markers)
77. [PMC12897054](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897054/)
78. [AHA Journals: Hypertension](https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.125.26135)
79. [ResearchGate: Carbohydrate-Based Drug Discovery](https://www.researchgate.net/publication/403989373_Carbohydrate-Based_Drug_Discovery_Synthetic_Strategies_and_Clinical_Applications)
80. [Diabetes Journals: GRP78](https://diabetesjournals.org/diabetes/article/73/5/763/154287/GRP78-Contributes-to-the-Beneficial-Effects-of)
81. [Indian Journal of Nephrology: IgA Nephropathy](https://indianjnephrol.org/state-of-art-therapeutics-in-iga-nephropathy/)
82. [OUP: Journals of Gerontology](https://academic.oup.com/biomedgerontology/article/69/7/779/662651)
83. [medRxiv: 26351390v1](https://www.medrxiv.org/content/10.64898/2026.04.21.26351390v1.full.pdf)
84. [Aging-US: 103884 Text](https://www.aging-us.com/article/103884/text)
85. [PMC11399422](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399422/)
86. [ResearchGate: The Immunoglobulin G Glycome](https://www.researchgate.net/publication/404121024_The_Immunoglobulin_G_Glycome_A_Modifiable_Biomarker_and_Functional_Effector_of_Aging_Disease_and_Mortality)
87. [PMC9815111](https://pmc.ncbi.nlm.nih.gov/articles/PMC9815111/)
88. [PubMed: 34399524](https://pubmed.ncbi.nlm.nih.gov/34399524/)
89. [PMC8096726](https://pmc.ncbi.nlm.nih.gov/articles/PMC8096726/)
90. [Lifeboat: BBB Glycome](https://lifeboat.com/blog/2025/04/disrupted-bbb-glycome-in-aging)
91. [ETH Zurich Research Collection](https://www.research-collection.ethz.ch/items/bc88797e-58a4-4d10-b809-2de1bc1ef51d)
92. [PubMed: 39383621](https://pubmed.ncbi.nlm.nih.gov/39383621/)
93. [Reddit: Multiomics in Aging](https://www.reddit.com/r/ketoscience/comments/1mah5sk/the_emerging_role_of_multiomics_in_aging_research/)
94. [ResearchGate: Multiomics in Aging Research](https://www.researchgate.net/publication/393846277_The_emerging_role_of_multiomics_in_aging_research)
95. [Frontiers: Aging Neuroscience 2025](https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1591796/full)
96. [Aging and Disease: 0218](https://www.aginganddisease.org/EN/10.14336/AD.2025.0218)
97. [Epigenetic vs Glycan Ageing Clocks](https://glycanage.com/blog/health/epigenetic-vs-glycan-ageing-clocks-which-is-better-for-measuring-biological-age)
98. [PMC4049143](https://pmc.ncbi.nlm.nih.gov/articles/PMC4049143/)
99. [Biological Age Tests Compared](https://glycanage.com/frequently-asked-questions/biological-age-tests-compared)
100. [GlycanAge Report](https://www.longevity.technology/wp-content/uploads/2022/03/GlycanAge.pdf)
101. [YouTube: GlycanAge Presentation](https://www.youtube.com/watch?v=xoGthp_U5cI)
102. [Aging with Strength: GLP-1 Primer](https://www.agingwithstrength.com/p/glp-1-metformin-and-rapamycin-a-primer)
103. [PMC11812426](https://pmc.ncbi.nlm.nih.gov/articles/PMC11812426/)
104. [BioWorld: Multiomic Study](https://www.bioworld.com/articles/726345-multiomic-study-shows-antiaging-effects-of-glp-1ras)
105. [Aging-US: 101319](https://www.aging-us.com/article/101319/text)
106. [GetHealthspan: Optimizing Longevity](https://gethealthspan.com/science/article/optimizing-longevity-protocols-rapamycin-acarbose-metformin)
107. [Aging-US: 103884](https://www.aging-us.com/article/103884)
108. [PMC3376388](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376388/)
109. [ResearchGate: Human Gut Microbiome](https://www.researchgate.net/publication/225374456_Human_gut_microbiome_viewed_across_age_and_geography)
110. [PMC5481955](https://pmc.ncbi.nlm.nih.gov/articles/PMC5481955/)
111. [News-Medical: Global Look at the Gut](https://www.news-medical.net/news/20250123/A-global-look-at-the-gut-Scientists-highlight-microbiome-diversity.aspx)
112. [PMC11399422](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399422/)
113. [PubMed: 30107893](https://pubmed.ncbi.nlm.nih.gov/30107893/)
114. [PMC4956791](https://pmc.ncbi.nlm.nih.gov/articles/PMC4956791/)
115. [Aging-US: 103884 Text](https://www.aging-us.com/article/103884/text)
116. [ResearchGate: Glycans Are a Novel Biomarker](https://www.researchgate.net/publication/259270172_Glycans_Are_a_Novel_Biomarker_of_Chronological_and_Biological_Ages)

**Sources:**
1. [glycanage.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGus9v_UEl3QQegyKzBu6EGwWSpopc54tBQ7SOo5NsiTXlqifSRJXIanIp9_tHEHNP_UQop8w86wctTPGvPUVzHcH_PBywzlaXtSTNLgV6cYReaKo51rD93VWBZ_zA8g9NTw-GOQtuE5VbfO04E5U8i__Yju5rvRJnDCw4so3dj2ffwtdk5Gf0eGIZq7NGMb7tgxOLG4aGo6qyuzYV2Wm6-MacKEfEO)
2. [cambridge.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEBEPtY_jTJ76h3zeAoq8HWhmtdv9m3_zwPYqRIFNBnIfjgHeXPl93pVGQQbRYoMBreyQy1jX4zXrn4FgvelZLIk_WZFKzysvG2icrvJaSccojbO_FleLnrbXLbW5jbXmNnwVkwnepezIyKARC8VUHGnnE-BcAGDMurRLrEZmb2xsqqzuI2dlyI4l3-I4bdpw_1fbAL6W3xzDD9LlfB01F_wPCv-EByXXOHeuo9ki2OCOGzmAyuf8i9kNnAmHr9Xey07s4Hm-iJFzO2GzkPVOs2bGHtvOEiJLJyH4UZBJNVpbsnBNKdWezT)
3. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMGVQJCbtKwdxq8t9ElwZQj2sPr4szdaa1BggfdKjNW0buoU8K-VNVHHruPxxFMpYUiOqM2WH8CwdR16Htcbc12b2P_OsXmMRTI4ZhGkx6XeXp2XWx4azFJk0XtYbz02rAPWyBTmHfjSGFbi4to9O7PWA7EJN3ilaidvAG)
4. [longevity.technology](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFYwGip5mRmFFjMoUR5otUTvhkSQPSEWAsNIngylAiyBTQwBdDwkmX3xuK95_KjXRZ1wHsTjWf-Lb-SlwXtx1tsIyAmT2IHedvTxQOBAyare0hNoojXjopVR6fiPKjWUf81PR8uQ-q6C1IUC4odjePQiASOKfBV3yTIa-GM9Vs=)
5. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFYFc8ut2H2ono5IGvyhfNS1SAAUXIQwLQOELBOWVdq1DD989XQry7AaG2Y88yuJd3YO2AjyiJ6MMPIJK0kHnjIHMmaqq0BVVRxpKFU8cijlf8IKJZvmvkZmiaeCDS3ERRaZ9pqCBS-)
6. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGFkCD41jz58Azwcg8ueoAKb7zQvb7W0vvsnwD52hPO75lINVBWsETjMQk8EMSPmX7S7NmFFl8mJEzAlXlfk-kh0waQGQUpisWDeVp2xsQo8JoXBkqI8O9MbsNhUFd5swKAq-swBzbo3JftxpZWTNNRe2pGrA6RcvifhkVGbtzJCS8G_hZpvoeXXftz80l0CL5DaD6SzoCNtYq_RYcAatAylnbfRp4tmKo=)
7. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHp1ZFLILYfuO_0H9XzOLzrfnq13e6wa2mv_vf1IuOlUNnc-6Rd_qA3vcRjWTViTDZRP37hareWgXrvr6-l0com_-OAspHOvas9IsVIx_HesWl2CBR94kM3ytgRLQDv)
8. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFYdkWEaS64LgQosnvA7OGuH_9eI3xIlHVJnUxoj3WD5ktSx3PiaDOUjwu13t7BdxVIHnWgbJLlCToBfGeihqKS0pE-ZMocoYZokpnqe2h1O6WbY_o2NZVQvfn5q0Up)
9. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH3E34uP-Sm2rJTCsu7-HMWZHUxS8QS8DxnNbXC8zNhOTl6k_s8oSnC8urIcCwlsW9dNztiOVz0-BK0sbWrZQH0Sz-JqnxEvwQm1r592e4vv944pGO4VWPV5yErMyXkIgOTsHS1Wio=)
10. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHEfyfGJidRgwsFKhtzzniP-743U0NbT0RIKR3gQF1K2_myDarKsFP9dYDYoqrDgMTzzNuceQFKTdqItFXUL0euliMR6PmEIbsgPSub1PZEu8otPMYnGdz_WIS8z6KifQuutc8MizK0pFxjzcPhBiqEFnp4s3XpMH7yBKaQ6kFm2oopClixk6u-82q5rA==)
11. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEsogJj1K4lyzG9RSfldBHG2bhZKsQMVwBB_M5jT0fWWptQgWk1p81V_Jjfeqs8ueogB0ZTvW3E6fKXCgSV3Jg4Qx5lx9Smq3QGFNZOv97cywOC0YOFo-W0NYfyy3BneO1ei6EMZus=)
12. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERi17CC_uCsK6yo17lqjGRnjap6UF7Ce6dZ3Hgmzofmuo3J7C68UPAgSvwpxUXGDhB7JHNJcQBY6LbM8Z8H0TLbkbmND-IJIIsFRTSw7X5_wF7LrGFrtR87-kRS9lIUa9JAdTc8ueApysHdZf-YFDP_tFR6JznE6P--dk8-ZXEbq3RqBd1Nlfi)
13. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGVH5uFhqnltKYIMlyTi9H7W-pCP6DG1DcL0Q29hsAnFxVWizUxTcwFbLPPY2BfFxNx4VXIB5rFv5zAmlxUm9IyXdobRHe_UYFabuQl1igynxGOGY2RDWK8CCXIlCuajdtAT1TAtagUnngjUVCPgU1Ud9HkYS6KCsuXLxa6d_Ke-8MKQN7go-Nc9ssRSDm2un0WATAnGL8HZsuWUt2tOa26AKJsrbaJBml5n6nywp2GUvRx_ZSRJDlHl1TFCmG)
14. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGCaZryxcTBB51_PtIhdDz9q9pA1GFNakSkTbPS7LKE0QWV1RgatXmMWJQg826QZYxMVXzi1dMmWP1SnD5ZDXqEDrRomGJ2fFehRYB8aJ9rg4QT_IjfAHfUqNPzWVVh7zTR)
15. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEvNZvs2e2LkoJTCXF6Gch6DLgtfYiPBDjCzTjNzF8lHyuRhiDVmJpxjdKRWvNga1Jb5dj4DtVngtgv75h99OUKvXe0M35RJkcpeH64CbwdGUer3ZBRKAl0XupzApwLoX9XI-WQ8X3KlfVKudlMS9csdIIV7Sh3JQ==)
16. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFalsN5xE4iP6CP1S3nsv8pFtx9vJToUWx7L7WQhrOxsE2a_7LmDXjPxddw6jiEJSutU40dxCGomndkPSQ1WmJsSRfeyLSm0DHHI7CC6zKH98XzobvHk2sHKUtPt9o=)
17. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFww5gFAn9e6tAHKQKZn2dYidf62YAQtOnWw8W8i87-bOteJe-xD6f6Qf_BA6EUAcbLkzJlGv1sgRH3sAx0UPDx6aSErQc1xRUKDO2GtZuXqelQvuDGu9ss4vfp5EhU)
18. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLLbUYzxUDn6sAmaslDvXVDMGIENX9yIr2xtQTVeuRwTnErNHWwvch-D-yGu-lwvjtFEccy5qHOxFJugd7jVrvj7vvTYOairn1T63ZDsutZWvNpxFJcvdhgkkihdo8u2iO42KgsvM=)
19. [acs.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdikCfL2rKs5NQJnsoXQOc7sAffPNhoVqtXJmDDrcWj0Rw4w7wNKlJitCl-s-AYJ4GLVqswFfJE5Jz-pdQcRCG-pbdv__6RqWOJf83L29l0YQMOScmqzk_ch7oG3oHbg==)
20. [arxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEyle0T8Fbr0HHX6kWi9fcXISKXhup31TV2v7d9C3lMGtDdu2WE85uZyC8s9qsO8M8jY8CVsSe3VL5Mll-Uulq9G41LiGOS_UvWqh5GxqCynoa0RpXvwhAX)
21. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFu9_WDI3ejrStnCilPILhaMTfy521Q4xqfI5msbdABDpqYHqQ6NYnAnRrwtFGl85GWae-tWH52vJRualToL27E67diL34C5zTY6b0WYCIhRVUOcrOdaI_D3JnZ7ozgxpiuw-CBhXY=)
22. [kcl.ac.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFxyuYR2wvDsgHMzTsHKsfODEXZcVnnvgazZUIb1tYtrUcuDpFNuCHhaXpN2RM9GHgfwDL2C2xWbRz3qA8HpCR38vkJLD6ewDDBqajj9N55GunbTO3HOvJ0_L4sRynjMZU8fuyiaxjhhecRCr1kAkdQRKARfrVHQFIndbcC72X-meJvL2zYCpnVrpKVfTiKUijc_6zi7H3I6qitFINGpgTy0UO1L-Pkbk=)
23. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8klVIF1lSUoEiB02_3COH9CNnaDtTKcZkJGBPHeher8Rp42nyFkkkfWRYdTVMD7fJUa7xV_XTeXn49xY6zFAw6WJtIN6XeYt9tHJhvsCyHyo2nHPXu_8xL_HXDFeh9W4xI1pq75MSs0U14tdICNmYkEFK5idtOXr-8ieFG_ZVHGOJPFJm9owr4OACVEjFUGKSNj0xgIiwpYL2_o9JNoRxdl1jZNuCwegoDw==)
24. [glycanage.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG_sGXbTrUP5968CV6V_EzMJ7uJUYPqW_G7KJho1J5fALQYa7vjC5GuLKl_wxqmgWZIpoJ6u6-7kl5CplIdMDuuCpRHFelLvG0rZs7CL_7eY1NQO06BVoL2MXyDYpAC7eUkK5KUKe5QC2JNuOHv8OzisVi9fympDSzrl8edvnbRDRnl2g==)
25. [patsnap.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGp_kvGqmmpbxgSK7SneAVGVhPo_cmcwA_oCFba2tiyluFc361X6-vYtVyGO1W6_T1CVlKPrb2mU4uXcAHW83aswgLLV6QMkHyyn4HX-gDeMXUni6PSn8mHZ9uKx_mO31joi2_GfxJNcZSZ2ed5q2mjcaDYJ9F0BxoD221Aq0ZiIcA2jurSCz84kuazosJ9oxXe2hLIQxfIc-OQ)
26. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkmavqHw_u0OXX5OmQppirym8AXD7yoz2g3M1cDxg6I-qzFE2IwaaOiH6kew5DSwwNJXnrszvm-JCc-nAXbfudezIHZ5sud1ZLUTxEMuOwc_Y3lPcbcHvlY1PA_5wt)
27. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXvMxIvzrc6qtWPjy5aRJ3ls1Ihlk3g7Qr3D9V7RbV-8r8JKemUS4g68-N4nfCX3L4Fn06esj96n_eHJUH_1b25GnfyYwK2lF1-oAzVI-3wki9Tx2rFuOyP9PQCNYt4Mmp)
28. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwwp09NptajSWfW2HvIbZyeP8YBUJcVZxYs_zrEj8GsLXQTeM-tPNUYwn51g6tlj0STEkCBcsBJckwmAwnsB4ARToU1zhMpFH3dBqwhJstV-InSdRGJqRRTFVogQoCgM367x2dcpA=)
29. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHe7rIUK9BWW4bC7ybC6gxwIMjrzXZpYej2Uh8FcKn-hNfcghOoBgXId_tKsR-qLHReW5vJWfDTCH2d_ggCgAQ-Wat64HoXmprsFpoJ_ncAMBg-BCF5v7w3mvAPVUsvO-QNwUcF3FWJ)
30. [lolahealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-6CCH8dYUvR136uBSS2lTAqmwt-jh2z3r5Gboo7BDe_r8Cczy0Sqx5XN805VhQ3MXamGAGWxTwTPodBVUEu7RxqTX6yz3RE8YUt4UjsXYnQBs1piYlTufAAG6D0rVpG3l6UNiELrTBnF-ApC9NELxzK8ITSooOU_V2UgVftIcq2zhtKTBJXbPHfGmyOSmOJj3VUgJc5HtEXxu08_A222ELUo=)
31. [letsprolonglife.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGt8PCXahn880NRHRQ6EZMzk_qcioLCrQWORqFZgUDE1RKr-alyUW9JESqZiz7Aee7vMz0kJzZ0utUNGgDi_SSNQkN_cj9Q9acu7Ob2vnkVJjG5ujiauNmrcRSc8WPxoOA=)
32. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYrfCQgVMzY7OpDSq1GMR_5d0lX0rRX9PxV7GYZDH9QtBgH0EgwLknX6YGVrVnC4_9Fn-tjHSCfs9VZYTYl54JPxb5s_rvVGEUnWpPZZ5c5crvedfPWkTocltllyUKnyaIAfAWdzk=)
33. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWI2nqSYOVgjmai8isWqGY6-H3lL8hglqC_65Wah6BDIpBJNTfOBe6ykqmMLCzcIq-tmWMYhZKQMSmOONI4X157lptZDmRExNCvJdsvqM1bP_-73xBo0t7or2hpoHwK64inEXesgreeXCl04NZIm2j_97-GfNx3ioocXB0gIW3NnZio_XCgOnMQoAptg91kMLqPk8Z8I_D4ly8yzhObCcUbajmcLGQ88dQkDooc2puX4mteVkA_aRoHABx2tfQbEsOg6FAR98HGpxPemrfXCkp8B1j)
34. [engineering.org.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFabxLYLHJ55QRFiSk9M4PdZURvqlqyxwxFl2_Sj7F7wloPVgGjgfNp4xeIbGsu-q6SmDb2kEWYkNb0DoKMbULg3inixahoZp_Lh2xmUl4VwD213cAm_mGjeoku1zHTpgnYtHqzfi61ULJC5rqbQJvoOg58a8Q=)
35. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgpe46qBwK0K6FzhXa03nos62Kbc9EIxG3TwECuAJitGC9VJ3TmyCVvQIIHTjPqlHQkUTIo-h_R1bLivMW84pqVAe8v1_Dl5iD9y2CSUSpiFfobqEHfUGki90Xa0NZnWppKso3Ho4Od4uQihgbtzFRaqJQSshJBpnzlg==)
36. [engineering.org.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-STXr5IqwBcMDquYv0tGGsA-wcUcWVyfepIco2WYRB0ZcnEb--OaAfGe1r6SH-kL9WQ0eftQMtZzabL0vbidxr0xWWcSk8JzUppe4s9vP1KOZf9tvDwIvCGB3jnvt4JLOokMA2GVDc1RY1L08Ly-_1SS1Nac=)
37. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHB5mAc0rSA4XIQmz6WHTrhMlq8YYloKttJJVJhDiNU8_cpc9s57og5j28jiSaZrUiJWSvU_m3dV033O4XUuoLgn2YhUbFD_fhapUZi1PBbMeFTQSVDAq2m6vWzRSn83rJ42HXJqhACe9fBjGWYa_l_34cGRmIJGRyZbX2wiaAGwNku3ecOoV7Lhb00DoE6NPH_xz0wm2Wv0Co=)
38. [aginganddisease.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4SRuHp6xtNK-iBKBPgfIPfyBNA_Fu6JS9-7QDn_AdGBAQoJm2jQ-7P3QUyTNzAJFklQJdcle0qZbh8Dp60MZRhyt0ldt4sJZ6xcaRn8yhLJG-VVZbs9DPwU8YwXB0wRuMHS-FLLlnx5cVcLbt)
39. [reddit.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHCXP9YLZeiiFoYVa2-FH3baBuw8jZRGygL-ZnZo2eAcnIVD5A7s1GmDuJ_jRsdCDm0RsdQS0OryqSF2BeDKbD61f3PfE80iQOqSEn5x7GMCpxdFQRo_4IwM8zUM5sOVVaWgcLi1-FHhsnyeP8Mm0cf1X0RVi42GhnX4SUx1Q75Olrw9U-wR7XkcHiP-oVdUOe4pL318DanrQ2hTn57)
40. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpTjiRfrmzhIVM86SX9qOYzdiV5sL8EWjeLbdcq3sArwO0umKqwjE_UvPf9Br_EjzgMIAmOZMjYteVfszupKI0QpQZ6XDCs24XmRIXmgybwkvt5B9eLXJF4o5wThqj1OD_ErBQwoE=)
41. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE47iE0PuVsbsOYEoinC7ltNiDGNdgA159ZCBwGKCMbhdSamLD7AO-yyPRqA35THSx0-XuxTyVzF81rJ15x5wuZhRFvaDXs9h7xKhyIxtebA2Mw3FsxGRles2Gub6kqKFvGvy7R70KbdRR0aZOV7otsksuEZ5TeKayaWzaX)
42. [glycanswitch.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQrau4c3RTXbiZ-b1VTrJFxZ5dbgkdn_W5w1GFWKYPuvA-Ym2DZUXx0pzybu5BeCDdX9OPyR1-4b7KYs0hicUBq_-xqeMbS2FWyJrykkVBScDQjT7OcE5nwZU=)
43. [lifeboat.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuZgFAm6odYpZEj0lDN9j_t_7qFZO85dvKx__iefbk3onjk9vgb5GMPaGjMMgWPpzYcRz8UYq6cgRYTyIaFRcC6cK1TuaK7oSdxbJEpw7v-lIlaDJK4geM5WG03NxfHDioYYp_2Ov2o8ObWLwzsR1UsEM9upg=)
44. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGoT9HxMCsQz7U6AYtUp7U1gAV4QU8zyz-gkyxN5iL0WNmbZYSD2ht0BxRu1mSOgxFfzHc4s9rXHcVcw01m_aNBxMIsmU_blotg-6wcxFyt8Z-94Agy-Uq9vGRK_EVYo2kbwvHpqMA=)
45. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGkFzlr852lppZ099pGtioFEgSKdivQh5x3tBTINJuZroN9ZR9MzhmHxmlzM0pRMnVQeb1AcxbhZ3Rkcn-I89A1txZZM16JsNqz0hjl4T1wv13yNzLLaRxKIOC7Cz8h_s7pzw==)
46. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFBS-zwzvJIq8nNe7Wi_x4vLjdf9i_FBIU_mAJzcf8LgJe69IKzX-prd9lbOZVmVHbK_w0Rpxh4THgRAdA0kbrgRB6rACOz5GSHbRZ4jq6wyqF6VjhtViyb_H31S3g7UdDlqirVEek=)
47. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWjvCmKoDAh86pYH38uAMU8UIbd8nkZqQ0MFk0r4j4SOPTCGXRLDPjxDUcdW898DD2nMBtoU8lMOdUdn_xavIIlVNKRYofL9ukCef8mJ90ax7FR9Po9rhcrDBJzkCjH9_-8FO9Sr71)
48. [bidmc.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZbXUjXUMCKx90czMmKlj0brnryVvxn-nToJm8BI619tyz3g8VjdsUWdM5dHohwuwHJtFl6a4WeVmCs9sNbOxdmqjt_5gnr7ewj1Nua7NdpCtIjupMj9DNsefVd7wzUDvA5FVitumyQ83OYPtf77PlZ7vszRpJ8eHy1jeVTwFOVZz0ulAMjz7BA2Jx6z4wWUk7yeVaypPlkhvj110BhJvIZROAEBxHpRtJlbnKmG2TzmFr4iaT009I)
49. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDeX-1VjOVCd67hj-6htQrTuQM9NVeDdtSexTOL3Bx4Jk2lab726sVnghLHY3X9f8_x8aUbwLlQk2x2vytqnw8iDKmvKkH7lr0MEmmn0ToIMJYewo_JJ8aq4xx4tVG)
50. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOzv8wS-1o0R62EWeOe2WND-ZI0NXq9jWV9Og85dUjEXrLe3nbahrJk8ggVIo_1xuujEtb8D1_YGs_QKmnZ5-w3V54YUVvV6pVXvWlGMoUqh6t0LEjHpB2vqN5NR0=)
51. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFsXbNVznwi8145T1XhizeCgFZiFpj75hQJKu_uLAe1wSZKCgF1KAmjSK4vD9_pLTfcdpYvCG-8e6RVCzNcLhLO5HgcJBFBXoa5tzFtq463O7tIiHjMClUon9ZU5nhE2o8St8TbPfBt)
52. [agingwithstrength.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEHhhnKlDAkcj-jhrKu9BBaDys4UvftTnwpntW1HJzbYafMGieJYSLs6J96016ScLQq3FzIqxRoQkssHi70g2pb8LZ6q8hDfgASz_II6WgjubikXwOwj8igmKVmc8rxX8tUSXYH2dTL4gsD1Aca3atQrSocYr540b5H2cXVTT7i)
53. [nmn.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-ztJQrSzKbT1WHW1AiFlnGXVfCjVthzpPR7GdRvRAVEsCiba0KEobVKWGmUHUIwWuIJDP85FbOlDBUdJFa0CGEWhzS7b2O98sZOnRnV3uD9w8r9-fn7OOBHNrq5bMsEpQQPDaKc8IijhrGixvdeNY3LKa8IG7J09Q-LE_vHZInbu2WLQf2ousXYIgnebsXG-gww==)
54. [bioworld.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErxyOtLSSectQtNRRGKuwMnxRtWIShIteIiO3gaX_JHL_hct5_wnW-DlfxO_KX0VRLtPr-4nNbpYBqFmRTzh6si6bnlrASjzN4Itq17VbjVKNojeMGfoWWYGSLPbEqhqctB3caoR4jWj1rl9jXfCE45je9CkbuF94Sp9MUbwrz-b59FZP_aZEo9XGV2aUrAvz1)
55. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFg7QfLcatcbm4sNMK17s_3EMedm-_VVwAxO2dIJ3f9LHTiz8jsJRE8CPw7Steh4HE5vRm99FGtXGDsiuRDDWCQW2hbJuUPCH_sU-vfB6_etaQNp_QI4lABlukKVWaFNzr8LrCl1ooH)
56. [indianjnephrol.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHElvEXhNM5NXg06TXzWjRjqKu_F_HytQQSUQoL0h5b5zaf6_6L2FmiBMnGSxW0heJIa_xGBmB2I52yQCVfBcwIRmrZDYRbIgJYK1h2MeEGbn1W73pXO6H8RzSu2ijrCjLBzv99CPCfTUMBDBgzEX84k5CAysxmtMtsebPSjQ==)
57. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGo7AhuOqZ9w54ZNCDAYxbwXAW4HjRKdLBMNei4wdZmQQuLFSS8kmlT8VvikJrDbWyPWLwr9ICBNdhU_5jJJDwHw3Oa1TkExuZrtkfZT34nsyS9mxW3hC54kAZkg8fo3VeijiB1z7k=)
58. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEG9zBW6jchO491FDy4dXYOrX0N8KCoFYvtETuJDxiv_7s2PahbZNSf20Y4KbSoO4JZ3MRKvvVK4hf4DfSNSjN2uzT0Oitdg0Yj5neRYZw_Jk4pHGByaq4A5Z00tqVd3KQlwsrC2pAihpJ3X71fmUzxhZZ18Yt2XSiKKIoGyuLbU0gay9-kI32CwiJ4UijT5fDandSwPf25PjuVVRJPMgtY4dkazrgwrrtraO9PIPVaI9ssmsjCFTk8VE8oQarn_A==)
59. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEDp9y8tlwKnsJgUbT9kLlPcw5oFsO1rwvzA0AVtCfuyzy2pY6HRdHyPdQD3-g-EwDpmypdTB_th5jcSWN9O1EZnUlhGto6LDOH1FyaBq2i7l6fe4f-p8sxiOO2L_2nmSAh4TR8HDa)
60. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHTn9lbMhjaTfm_0QL5fLMv_DTbL6fDfvwSwz8SUwld2MvzeIooRf5RyKEl-3S7IeyGNPodRvbzSHEWWNwe2wZqF_4z4K4nBADUHVtZPPDlu5PbGoWDPW7snFXerwo8bJI5f63e3BQ)
61. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHaA4EV4jHLZHA6JqRL3yRb3kE2r8_K6cNdvGZ0AafOkCeuEoocBUsNQs3s2AupHbV-E46GF1TZyY2Yh_xf0lBdB0WclQRwnV1z8O4baXn8rTxp4FL5cMdAjBHueAcNHAr6)
62. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHpceeE1YLNp6TcAW0hiz2IxAJkwtkIrctZrZJ3grCOChbcPEKcUZCkwKnfdo36n3Au9LKeGks_R_U_sOxcuNhNKOrt44bJhujxh388YNiZfUogwT1CEEECtv6N58Y0o61c7cDYYyeuT4HBHTBovbdQhtoe0DkP2EqrCg==)
63. [gethealthspan.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFmDyMqYeVabujgfk6k3XeOF2JbJkX90C4Bt3QXNdoba1WQODxnUVCzX_L1JVJbs0vh9fYZOnWo__zQmnubbShhlIjn8KjT9Y_FxykX_f5rWNMyxkRaGFsB2XF8WIO74ziHSNJh3DALKSxKleedOzBeh5j1gWNfn9zizejCFF0_WNPKCzbVMS3gExwxvhECIsUKOoeJNqvk4pxp)
64. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiD-pZos9B6rpbXtu6TCpm1QdbvwI6V0g68D_bONoiQ1OwzUA5Y7ZA0GSNlSVAFR6hOV2FbYttpS8pzUy99SFI2m15mnU--H7OXxxLsPDuIS4HKi-1dm4KDhZ6cN1mbI41GySWAzw=)
65. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFC4I4KbTJ6FBHuzaEYq34sISBjBWXSInCBOzQCnB7Pqj1ybOOk-z7Jg4lUtLxwyqIaasAVGpmDEvzA4fBhmVx087mKklYmmAwcgPNTHy-33cmHkOCmnxehhOyNFA==)
66. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGkXVPxT0aKPtebcgMwjaE-yyEoTU-VI_ItWtaQP37Ix0yCjUe_QiugQ_JAt4_zbJXX_kcSI8dTGwE6NWRLc374TfXlJrgkuKgz5Y8g-qbz11kSlsgtGsAVy8j6UJVlQru0hZS_Nma6X7rJLHMajNA=)
67. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeS6M1tiNqvLL-HzuGGvjA5qec_y8RfUX1Zj-R7_VknOd10dARcn7V_feom68qz4sXG9n8yE4zoM1CS9qJXfkNbRYrD8rHPqw1YnjBm6SJ2mkUVXUa4SYnNlBA_PMPQLn_ES4g5QedHuXAREZTEIvZ35yhhswsCXGp1hnvLpx9olIt1s3SQYytfsU87E8bzZjlnng=)
68. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHAa2HQg6Guvgb4K76jGKadKz-fd9M88nlXNaFWS8bpSSYg61eeIQJmDbDD51Q-EMxVVgAs15kpksxwhHO1yaU8rn6OvDVkYq5oo9aLOi8WlgR3L-IRPiLQjOqOAOEE)
69. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFilwe9_iosttkwNSh6xvvjyhVuN2KXLsHuqy53K8Am2f8fork5gwbBgGNhAO87Z48M6hfDKYatzOB1PmXEK4XMazM43XNyUXSZekXEHQYqq_cCtFPGBxwN0zjdTVFUBcl_92eGEGM=)
70. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4PZI3j_qMYlfpJkYcuHfCKr3n5QN17OJ9EBp_1odPmgyN0BEV9mr9WD7x3W-uniVCIlGGLHA_ieZ_Xtp90eaLPxXhDMze6hFm1wnztsTq_AfEo-z8uU4F96IH3orA_4uiq8oS6Ye4-Q5QI6Nbpxvy0OmTDRpzAA8zzXils-1CmUdBCUZCvPvjVgNgnoNwqT_h7Xgd248yiqhxklc=)
71. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGE2hDD3tEw5GMp_TxhBEGZKy2x0LzNDWsPCrEPXCbPr6ZY3fIIRbr-iP9jqF7TPeSqM-Z1WAzawMB5XZKmE8BkvlS9N9autF7gk1DjMsYOkSRmUNuy4IJofauFHwBziaRV15qRRFeCtwpP415brQgJFRo4PzavBvw7zoPGEVZGVA3JINabDgZu_YJ6cukmfE-lnTqJdM6H-Spuhyjywy3UThtmYywkMg==)
72. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFhoDH-YaCBh8blqw2p4hAESDwAQJ9D86scuujf-JfwWWOA926baGs5SIbWZyOu8rdXRvsYY8VNGmrBY85d_fqwQ_ZQ1g2enY849SZKjcuAzBSO1nyGyrr8wc0Aj0Jq)
73. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj8xQBdJWYc09QHOToAyHYYBOuY9ddqobMNJklzOTr9N0NWVs-SvBfxpzo8yXgSwO7RfYjl4NtZ2h1ADuInpAsKL8zrZFQA1TrcNApI9UAwoCYeXDdBKN0IpIf0b1XsM3ZwoMHUDQ=)
74. [ethz.ch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-zrGEM71lJUGKt-s8AG6JG3Z3UY8yvg8gmuy_Ovj8wKWSfRiuoWqf3Tcth7M9RW17z0pazgtng564nwwtOQn3ESvPl194pQ2Dfu_zz29S8oQwtqmrjCeeZ0S4v4hZ733oyJBPztUfEnvx-3Nrkbj3k6WUEobaCtbjgR-3X_0xO7M9NMdewbc=)
75. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0o-aDcc_FeRAUPejlA0LosqXKov88ITWulv8-6l4osyZijNvbc2FyiODBcT4DCcyzKJWs1jyNNYd07IsYaQ4-nb7kFHrI5cV3Vn1znkaLboTc0pt4VXDKJ9-PFaefmj4jUZfU501QHHqoz7PnsNN5qpiq2mk93xolEfccwdHQsKYNxh4kSPMcp1QYNoXprFUvx1M8zB2FRhYoNeEuhZXZhABeYQH44EYs9gx7ApkkeGB3lXGKfEC3vt4m6Gcu)